Furthermore, studies have evaluated the FRG AKR1C1, revealing its potential related to the immune-microenvironment, which may further affect the progress and prognosis of patients with breast cancer, making it a novel biomarker for the immune microenvironment and prognosis determination of breast cancer [73]. This evidence concerns the gene AKR1C1 and breast cancer.